Novartis to acquire Anthos for up to US$3.1 billion
The transaction will cost Novartis US$925 million upfront with potential additional payment of up to US$2.15 billion
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
SWISS pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion.
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent stroke and the recurrence of blood clots.
The transaction, expected to close in the first half of this year, will cost Novartis US$925 million upfront with potential additional payment of up to US$2.15 billion, the company said.
“With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients,” said Bill Meury, CEO at Anthos.
Reuters reported in December 2023 that Blackstone was exploring the sale of Anthos. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
